AAPG
ASCENTAGE PHARMA GROUP INTERNATIONALASCENTAGE PHARMA GROUP INTERNATIONAL reported revenue of CNY 980.65M in its most recent fiscal year, up 341.8% on the year before. It kept -41.4% of that as net income, and generated -CNY 135.65M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | 341.8% | 12.8% | 13 / 159 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | Not reported | 12.2% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | Not reported | 12.5% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -1.4% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 0.6% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 0.0% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -4.1% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 97.0% | 70.7% | 9 / 106 |
Operating margin Operating income as a share of revenue. | Not reported | -15.3% | — |
Net margin Net income as a share of revenue. | -41.4% | -13.0% | 111 / 163 |
Free cash flow margin Free cash flow as a share of revenue. | -13.8% | -2.0% | 84 / 144 |
Return on equity Net income divided by shareholder equity. | -148.0% | -14.2% | 151 / 164 |
Return on assets Net income divided by total assets. | Not reported | -9.5% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -6.1% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 6.09x | 0.43x | 84 / 86 |
Current ratio Current assets over current liabilities. | 1.26x | 2.96x | 161 / 189 |
Quick ratio Current assets excluding inventory, over current liabilities. | 1.26x | 2.58x | 151 / 189 |
Interest coverage Operating income divided by interest expense. | Not reported | -0.74x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Annual financials
| Fiscal year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | CNY 980.65M | CNY 221.98M | CNY 209.71M |
| Gross profit | CNY 951.57M | CNY 191.44M | CNY 187.71M |
| Net income | -CNY 405.68M | -CNY 925.71M | -CNY 882.92M |
| EPS (diluted) | -CNY 1.34 | -CNY 3.28 | -CNY 3.35 |
| Operating cash flow | -CNY 111.36M | -CNY 726.08M | -CNY 653.91M |
| Capital expenditure | CNY 24.29M | CNY 46.11M | CNY 203.29M |
| Free cash flow | -CNY 135.65M | -CNY 772.18M | -CNY 857.20M |
| Shareholder equity | CNY 274.16M | CNY 70.63M | CNY 408.66M |
| Total debt | CNY 1.67B | CNY 1.80B | — |
| Cash | CNY 893.10M | CNY 1.04B | CNY 1.35B |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Amounts are in CNY, as the company reports them. Nothing here is converted to dollars, so these figures cannot be compared directly against a company reporting in another currency. Margins, returns and other ratios are unaffected.
Source
Figures come from ASCENTAGE PHARMA GROUP INTERNATIONAL’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 20-F filed Apr 16, 2025. View filings on EDGAR.